Russell Investments Group
ECYT

Russell Investments Group’s Endocyte, Inc. Common Stock ECYT Stock Holding History

Russell Investments Group’s Portfolio ECYT Stock Details ECYT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-5,772
Closed -$25K – 3079
2017
Q4 		$25K Hold
5,772
– – ﹤0.01% 2921
2017
Q3 		$8K Sell
5,772
-14,400
-71% -$20.1K ﹤0.01% 2917
2017
Q2 		$30K Buy
+20,172
New +$43.3K ﹤0.01% 2920
2017
Q1 		– Sell
-13,900
Closed -$37K – 3154
2016
Q4 		$37K Buy
+13,900
New +$39.9K ﹤0.01% 3004

Other funds holding ECYT

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return

Russell Investments Group's ECYT Position: Q1 2018 in Review

Russell Investments Group sold out of Endocyte, Inc. Common Stock (ECYT) in Q1 2018, closing a stake of 5,772 shares — an estimated $25K sold.

Russell Investments Group first reported a position in ECYT in Q4 2016 and held it in 4 quarters. The position peaked at $37K in Q4 2016. 89 funds tracked by Wall St. Rank hold ECYT as of Q1 2018.

  • Russell Investments Group reported no remaining Endocyte, Inc. Common Stock position as of Q1 2018 after selling out during the quarter.
  • Russell Investments Group sold 5,772 Endocyte, Inc. Common Stock shares in Q1 2018, an estimated $25K.
  • Russell Investments Group first reported a position in Endocyte, Inc. Common Stock in Q4 2016 and held it in 4 quarters.
  • Russell Investments Group's Endocyte, Inc. Common Stock position peaked at $37K in Q4 2016.
  • 89 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q1 2018.

Based on Russell Investments Group's 13F filing for Q1 2018, filed 11 May 2018.